Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of LTG-001 in Healthy Participants
NCT06049095Phase 1Active, not recruiting
- Sponsor
- Latigo Biotherapeutics
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing LTG-001 with Placebo (2 arms). Primary endpoints: Safety and tolerability of single and multiple ascending oral doses, relative bioavailability and food effect at 10 days, Absolute Bioavailability of LTG-001 Following Oral and Intravenous Administration at 35 days and 1 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
LTG-001
03
Conditions
pain
Beyond the preview
Go deeper on NCT06049095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049095.